High-density lipoprotein affects antigen presentation by interfering with lipid raft: A promising anti-atherogenic strategy

Clinical and Experimental Immunology

Volumn 160, Issue 2, 2010, Pages 137-142

  Wang, S H ^a   Yuan, S G ^a   Peng, D Q ^a   Zhao, S P ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Antigen presentation; Atherosclerosis; High density lipoprotein; Lipid raft

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; SIMVASTATIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ATHEROSCLEROSIS; CD4+ CD25+ T LYMPHOCYTE; CHOLESTEROL TRANSPORT; DENDRITIC CELL; DRUG MECHANISM; IMMUNOMODULATION; LIPID COMPOSITION; LIPID RAFT; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN PRESENTATION; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; BIOLOGICAL TRANSPORT; CHOLESTEROL; DISEASE MODELS, ANIMAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; LYMPHOCYTE ACTIVATION; MEMBRANE LIPIDS; MEMBRANE MICRODOMAINS; MICE; T-LYMPHOCYTE SUBSETS;

EID: 77950643696     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04068.x     Document Type: Review

References (71)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999 340 : 115 126. (Pubitemid 29054847)
2. Libby P. Inflammation in atherosclerosis. Nature 2002 420 : 868 874. (Pubitemid 36019640)
3. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 2006 1 : 297 329.
4. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002 91 : 281 291. (Pubitemid 34976993)
5. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002 8 : 1218 1226.
6. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001 21 : 1876 1890. (Pubitemid 34219736)
7. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 2005 25 : 18 28. (Pubitemid 40054250)
8. Luc G, Bard JM, Juhan-Vague I et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study. Arterioscler Thromb Vasc Biol 2003 23 : 1255 1261. (Pubitemid 36871282)
9. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000 102 : 2919 2922.
10. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000 86 : 19L 22L.
11. Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007 56 : 1384 1396. (Pubitemid 46764065)
12. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005 25 : 1776 1785. (Pubitemid 41243443)
13. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008 121 : S3 8.
14. -/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. J Lipid Res 2007 48 : 794 805. (Pubitemid 46557884)
15. Stanic AK, Stein CM, Morgan AC et al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci USA 2006 103 : 7018 7023.
16. de Carvalho JF, Bonfa E, Borba EF. Systemic lupus erythematosus and 'lupus dyslipoproteinemia'. Autoimmun Rev 2008 7 : 246 250.
17. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003 48 : 2533 2540. (Pubitemid 37129431)
18. Bresnihan B, Gogarty M, FitzGerald O, Dayer JM, Burger D. Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? Arthritis Res Ther 2004 6 : R563 R566.
19. van Halm VP, van Denderen JC, Peters MJ et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006 65 : 1473 1477.
20. van Halm VP, Nielen MM, Nurmohamed MT et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007 66 : 184 188.
21. Wilhelm AJ, Zabalawi M, Grayson JM et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol 2009 29 : 1 8.
22. Bensinger SJ, Bradley MN, Joseph SB et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008 134 : 97 111.
23. Glass CK, Saijo K. Oxysterols hold T cells in check. Nature 2008 455 : 40 1.
24. Brewer HB. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004 24 : 387 391. (Pubitemid 38326126)
25. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004 95 : 764 772. (Pubitemid 39390578)
26. Yancey PG, Bortnick AE, Kellner-Weibel G, De La Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003 23 : 712 719. (Pubitemid 36566157)
27. Yokoyama S. Release of cellular cholesterol: molecular mechanism for cholesterol homeostasis in cells and in the body. Biochim Biophys Acta 2000 1529 : 231 244.
28. Fielding CJ, Fielding PE. Cellular cholesterol efflux. Biochim Biophys Acta 2001 1533 : 175 189.
29. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997 387 : 569 572. (Pubitemid 27248754)
30. Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998 14 : 111 136. (Pubitemid 29001451)
31. McIntosh TJ, Vidal A, Simon SA. Sorting of lipids and transmembrane peptides between detergent-soluble bilayers and detergent-resistant rafts. Biophys J 2003 85 : 1656 1666. (Pubitemid 37052248)
32. Brown DA, London E. Structure and origin of ordered lipid domains in biological membranes. J Membr Biol 1998 164 : 103 114. (Pubitemid 28336989)
33. Gaus K, Rodriguez M, Ruberu KR et al. Domain-specific lipid distribution in macrophage plasma membranes. J Lipid Res 2005 46 : 1526 1538. (Pubitemid 43109818)
34. Kenworthy AK. Have we become overly reliant on lipid rafts? Talking Point on the involvement of lipid rafts in T-cell activation. EMBO Rep 2008 9 : 531 535.
35. Zidovetzki R, Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta 2007 1768 : 1311 1324.
36. Chichili GR, Rodgers W. Clustering of membrane raft proteins by the actin cytoskeleton. J Biol Chem 2007 282 : 36682 36691.
37. Lenne PF, Wawrezinieck L, Conchonaud F et al. Dynamic molecular confinement in the plasma membrane by microdomains and the cytoskeleton meshwork. EMBO J 2006 25 : 3245 3256.
38. Kabouridis PS, Janzen J, Magee AL, Ley SC. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur J Immunol 2000 30 : 954 963.
39. Andeson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol 2000 1 : 156 162.
40. Kabouridis PS. Lipid rafts in T cell receptor signaling. Mol Membr Biol 2006 23 : 49 57.
41. Zeyda M, Stulnig TM. Lipid rafts & co.: an integrated model of membrane organization in T cell activation. Prog Lipid Res 2006 45 : 187 202.
42. Jury EC, Flores-Borja F, Kabouridis PS. Lipid rafts in T cell signaling and disease. Semin Cell Dev Biol 2007 18 : 608 615.
43. Setterblad N, Roucard C, Bocaccio C, Abastado JP, Charron D, Mooney N. Composition of MHC class II-enriched lipid microdomains is modified during maturation of primary dendritic cells. J Leuk Biol 2003 74 : 40 8.
44. Hiltbold EM, Poloso NJ, Roche PA. MHC class II-peptide complexes and APC lipid rafts accumulate at the immunological synapse. J Immunol 2003 170 : 1329 1338.
45. Poloso NJ, Roche PA. Association of MHC class II-peptide complexes with plasma membrane lipid microdomains. Curr Opin Immunol 2004 16 : 103 107.
46. Pralle A, Keller P, Florin E, Simons K, Horber JK. Sphingolipid- cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J Cell Biol 2000 148 : 997 1008.
47. Setterblad N, Becart S, Charron D, Mooney N. B cell lipid rafts regulate both peptide-dependent and peptide-independent APC-T cell interaction. J Immunol 2004 173 : 1876 1886.
48. Eren E, Yates J, Cwynarski K et al. Location of major histocompatibility complex class II molecules in rafts on dendritic cells enhances the efficiency of T-cell activation and proliferation. Scand J Immunol 2006 63 : 7 16.
49. Goebel J, Forrest K, Flynn D, Rao R, Roszman TL. Lipid rafts, major histocompatibility complex molecules, and immune regulation. Hum Immunol 2002 63 : 813 820.
50. Zilber MT, Setterblad N, Vasselon T et al. MHC class II/CD38/CD9: a lipid-raft-dependent signaling complex in human monocytes. Blood 2005 106 : 3074 3081.
51. Bouillon M, EI Fakhry Y, Girouard J, Khalil H, Thibodeau J, Mourad W. Lipid raft-dependent and -independent signaling through HLA-DR molecules. J Biol Chem 2003 278 : 7099 7107.
52. Ghittoni R, Napolitani G, Benati D et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol 2006 36 : 2885 2893.
53. Kuipers HF, Biesta PJ, Groothuis TA, Neefjes JJ, Mieke Mommaas A, van den Elsen PJ. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol 2005 66 : 653 665.
54. De Libero G, Mori L. Recognition of lipid antigens by T cells. Nat Rev Immunol 2005 5 : 485 496.
55. Cao X, Sugita M, Van Der Wel N et al. CD1 molecules efficiently present antigen in immature dendritic cells and traffic independently of MHC class II during dendritic cell maturation. J Immunol 2002 169 : 4770 4777.
56. Sloma I, Zilber MT, Vasselon T et al. Regulation of CD1a surface expression and antigen presentation by invariant chain and lipid rafts. J Immunol 2008 180 : 980 987.
57. Tellier E, Canault M, Poggi M et al. HDLs activate ADAM17-dependent shedding. J Cell Physiol 2008 214 : 687 693.
58. Mendez AJ, Lin G, Wade DP, Lawn RM, Oram JM. Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the abca1-mediated lipid secretory pathway. J Biol Chem 2001 276 : 3158 3166.
59. Drobnik W, Borsukova H, Bottcher A et al. ApoA I/ABCA1-dependent and HDL3-mediated lipid efflux from compositionally distinct cholesterol-based microdomains. Traffic 2002 3 : 268 278.
60. Peng Y, Akmentin W, Connelly MA, Lund-Katz S, Phillips MC, Williams DL. Scavenger receptor BI (SR-BI) clustered on microvillar extensions suggests that this plasma membrane domain is a way station for cholesterol trafficking between cells and high-density lipoprotein. Mol Biol Cell 2004 15 : 384 396.
61. Puff N, Lamaziere A, Seigneuret M, Trugnan G, Angelova MI. HDLs induce raft domain vanishing in heterogeneous giant vesicles. Chem Phys Lipids 2005 133 : 195 202.
62. Gaus K, Kritharides L, Schmitz G et al. Apolipoprotein A-1 interaction with plasma membrane lipid rafts controls cholesterol export from macrophages. FASEB J 2004 18 : 574 576.
63. Zhu X, Lee JY, Timmins JM et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008 283 : 22930 22941.
64. Landry YD, Denis M, Nandi S, Bell S, Vaughan AM, Zha X. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem 2006 281 : 36091 36101.
65. Murphy AJ, Woollard KJ, Hoang A et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008 28 : 2071 2077.
66. Banchereau J, Briere F, Caux C. Immunobiology of dendritic cells. Annu Rev Immunol 2000 18 : 767 811.
67. Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005 26 : 1700 1704.
68. Yilmaz A, Weber J, Cicha I et al. Decrease in circulating myeloid dendritic cell precursors in coronary artery disease. J Am Coll Cardiol 2006 48 : 70 80.
69. Shah PK, Chyu KY, Fredrikson GN, Nilsson J. Vaccination for atherosclerosis: a novel therapeutic paradigm. Exp Rev Vaccines 2004 3 : 711 716.
70. Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 2003 3 : 973 983.
71. Min WP, Zhou D, Ichim TE et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003 170 : 1304 1312.